Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Entrada is developing a cyclic cell-penetrating peptide platform aimed at overcoming key drug delivery challenges for larger therapeutic modalities like oligonucleotides, enzymes, and peptides, the analyst tells investors in a research note. While prior approaches using transferrin receptor-targeted conjugates have shown early promise in muscle disorders, Entrada’s platform seeks to improve efficacy and expand delivery to multiple tissue types, positioning it as a potentially first-in-class solution, Cantor says.